Loading news...
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic appli.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an ove.
EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e.
OmniAb, Inc. ( OABI ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Kurt Gustafson - Executive VP of Finance & CFO Matthew Foehr - President, CEO & Director Conference Call Participants Michael Almisry - Leerink Partners LLC, Research Division Alexander Xenakis Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Presentation Operator " Kurt Gustafson Executive VP of Finance & CFO " Matthew Foehr President, CEO & Director " Michael Almisry Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Unknown Analyst " Alexander Xenakis " Truist Securities | Matthew Hewitt Craig-Hallum Capital Group LLC, Research Division " Craig-Hallum Capital Group LLC, Research Division Brendan Smith TD Cowen, Research Division " TD Cowen, Research Division Unknown Analyst " Operator Good afternoon, and welcome to OmniAb's Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. “Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering.
OmniAb, Inc. (OABI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences during the month of November. 2025 Truist Securities BioPharma Symposium, November 6 at the Lotte New York Palace Hotel. Matt Foehr, Chief Executive Officer, will participate in one-on-one meetings with investors on Thursday, November 6th. Stifel 2025 Healthcare Conference, November 11-13 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Fi.
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter 2025 financial results and business updates Date: Tuesday, November 4, 2025 Tim.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expense.
OmniAb, Inc. (NASDAQ:OABI ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kurt A. Gustafson - Executive VP of Finance & CFO Matthew W.
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. “Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team's execution, and puts us on pace for one of our strongest years ever.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss second quarter 2025 financial results and business updates Date: Wednesday, August 6, 2025 Time: 4:30 p.m.
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, title.
OmniAb, Inc. (NASDAQ:OABI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matthew Foehr - Chief Executive Officer Bob Chen - Vice President, Discovery Systems Conference Call Participants Michael Almisry - Leerink Partners Alexander Xenakis - Truist Securities Joseph Pantginis - H.C. Wainwright Jacqueline Kisa - TD Cowen Operator Good afternoon, and welcome to OmniAb Inc.'s First Quarter 2025 Financial Results and Business Update Conference Call.
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts,” said Matt Foehr, Chief Executive Officer of OmniAb.